It's also possible the work may lead to new therapeutic approaches, researchers say.
"It's not completely clear yet whether the higher levels of CTIP2 expression are a consequence of cancer, or part of the cause," said Arup Indra, also an OSU assistant professor of pharmacy. "However, we strongly suspect that it's causally related. If that's true, then therapies that could block production of CTIP2 may provide a new therapeutic approach to this type of cancer."
That this genetic regulator could be involved in both skin development and these types of cancer makes some sense, the scientists said both originate from epithelial cells.
It's also possible, the study found, that CTIP2 works to help regulate the growth of what is believed to be a cancer "stem" or "progenitor" cell, which has a greater potential to generate tumors through the stem cell processes of self-renewal and differentiation into multiple cell types. Therefore, targeting cancer stem cells holds promise for improvement of survival and quality of life of cancer patients.
'/>"/>
| Contact: Gitali Indra indrag@onid.orst.edu 54-107-379-416 Oregon State University Source:Eurekalert |